In November 2020 we focus on MARC members from the Burnet Institute.
Burnet Institute is an Australian, unaligned, not-for-profit, independent organisation that links medical research with practical action to help solve devastating health problems. This sets us apart from other organisations.
Prof Paul Dietze is one of Australia’s leading alcohol and other drug epidemiologists with a significant national, and emerging international profile. He is an NHMRC Senior Research Fellow and a past ARC Future Fellow and VicHealth Public Health Research Fellow. With more than 20 years’ experience and an outstanding track record, his work has established internationally innovative surveillance systems and applied research designs that break new ground in the public health research into alcohol and other drug use and related harms in Australia.
Paul’s work has had major impact. Naloxone is now administered via the intranasal route in many parts of the USA as a result of his work in Victoria. He was a member of the ‘Guidelines Development Group on the management of opioid overdose’ for the World Health Organization, which met in Geneva in February 2014 with the guidelines released in late 2014.
He has been involved in the development and implementation of a variety of heroin overdose prevention initiatives including the Direct Response to Overdose (DROP) project and he is leading the evaluation of the first Australian bystander naloxone program being implemented in the ACT. He was a key member of the Expanding Naloxone Availability in the ACT Committee. He is a Chief Investigator on a trial of intranasal naloxone in the Sydney Medically Supervised Injecting Centre that commenced in January 2012.
He co-convenes the Victorian Injecting Drug Harm Reduction Network with Penington Institute through which research findings on injecting drug use are disseminated to the alcohol and drug sector.
Prof Dietze currently collaborates with MARC members on the following projects:
MARC Co-investigators: Prof Andrea Reupert (EPIE)
Prof Mark A Stoove is Head of the Public Health Discipline and a co-Head of the HIV Elimination Program at Burnet Institute.
He has researched the transmission and impact of sexually transmitted and blood borne viruses among key risk populations for almost 20 years. His research program undertakes sexually transmitted and blood borne virus surveillance nationally and within specific jurisdictions across Australia.
He also specialises in behavioural epidemiology, data linkage, and implementation science projects focused on reducing the transmission and burden of infectious diseases. His projects include bio-behavioural cohort studies of gay, bisexual and other men who have sex with men and people who inject drugs.
He has published over 140 peer-reviewed papers and assumes various editorial roles for international peer-review journal editorial roles as well as conference convening roles. Over the past five years, he has attracted in excess of AUD$25 million in research funds as a lead investigator.
Dr Amanda Roxburgh is a NHMRC Research Fellow. Amanda has 18 years’ experience in the alcohol and other drug research sector and has a national and emerging international profile relating to her expertise in opioid overdose mortality.
Her research has led to a greater understanding of the changing nature of opioid overdose mortality and the contribution of pharmaceutical opioids to these deaths.
Amanda’s work has informed legislative change in Australia (e.g. rescheduling of codeine and regulatory changes in dispensing of Schedule 8 opioids). She has led briefings to government (e.g. the Australian Government Department of Health, and the Pharmaceutical Board Advisory Committee), and written commissioned (by the Intergovernmental Committee on Drugs – IGCD and the NSW Parliament) reports which have directly informed Australia’s National Drug Strategy.
Her current research focuses on understanding the factors driving non-fatal and fatal overdose in the context of contemporary drug markets, with the aim of informing overdose policy responses and reducing drug-related harms.